Diabetes drugs become new hope for Alzheimer's disease treatment
January 02, 2018 Source: Sina Pharmaceutical
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];Alzheimer's disease can be said to be the most common type of disease that currently plagues drug developers. For decades, almost all human drugs for this disease have encountered Waterloo without exception. Scientists from Lancaster University in the UK are now trying to unravel this problem from another angle. In their latest article in Brain Research, they reported that the use of three drugs for the treatment of type 2 diabetes can effectively improve the symptoms of memory impairment in a mouse model of Alzheimer's disease.
This combination therapy combines GLP-1, GIP, and glucagon three growth factors. The researchers said that earlier studies have found abnormalities in the pathways associated with these three growth factors in brain neurons of Alzheimer's patients.
Researchers used maze tests to test whether this therapy can restore cognitive performance in Alzheimer's mice. The results showed that the treated mice showed improvement in learning and cognitive ability, and the rate of neuronal reduction in the brain of the mice was significantly reduced. In addition, the researchers also found that amyloid accumulation in the brain of mice was also significantly reduced.
However, this is not the first time scientists have applied diabetes therapy to the treatment of Alzheimer's disease. Pharmaceutical giant Novo Nordisk is currently conducting a small clinical study to validate its development of the GLP-1 analog drug Victoza to improve Alzheimer's disease. However, the current results show that the drug can reduce the accumulation of amyloid in the brain of patients, but the patients in the treatment group did not show improvement in cognitive ability compared with the placebo group. This is why the current study of GLP-1 drugs for Alzheimer's disease has not received widespread attention in the industry.
In recent years, the hypothesis that amyloid accumulation leads to Alzheimer's disease has been strongly challenged. Many pharmaceutical giants have suffered from Alzheimer's disease drugs. Lilly's solanezumab and Pfizer's bapineuzumab have failed to give a heavy blow to drug development in this field. However, the amyloid hypothesis is far from Chengdu, which has withdrawn from the historical stage. Some companies such as Baijian, Amgen and Novartis are still developing drugs based on blocking BACE protein to inhibit amyloid production.
Although the three drug combination therapy showed certain effects in the mouse model, it was far from entering the clinical research stage. Christian Holscher, who is in charge of the project, said researchers still need to do more research to determine if the treatment is worthwhile. (Sina Pharmaceutical Compilation / Sheep Pharmacist)
Article, picture reference source: Could a three-part diabetes drug ease memory loss in Alzheimer's?
We are an industry and trade integrated enterprise in China. Our company was established in 2010 and has 12 years of export experience and production experience. Our company has unique advantages in production of Organic Extract , because our Plant Extract is come from our own plant extracting, cultivation at the same time, our production of Herbal Extract from our local, our factory is located in xi 'an, China, where climate conditions are beneficial to plant growth, at the same time good plant diversity. Our company is also a leading China Leading Manufacturers And Suppliers Of APIs Raw , because we have professional Chinese Api Raw Material suppliers, we have set up a professional production workshop, standard production equipment, high-quality technical personnel.
We have advantages in the production of pharmaceutical raw materials. We can provide raw materials for Improve Immunity Powder, high-quality raw materials for Antibiotic & Antibacterial , and raw materials for Blood Pressure raw powder treatment. Meanwhile, in order to meet the needs of customers, we introduce advanced equipment to produce Nutrition Supplements , which are widely bought by customers. Our company has a fixed partner manufacturers in 82 countries worldwide, the annual sales of 30 million US dollars, the quality of the products have been praised by the majority of customers.
Physical exercise , Xylazine Hydrochloride,Amino Tadalafile, Ketotifen Fumarate Powder,Vonoprazan Fumarate Fda Label,Edoxaban and Carbamazepine
Xi'an Henrikang Biotech Co.,Ltd , https://www.xianhenrikangbio.com